Neuroaid was first launched commercially in Singapore in 2006. Today, it is marketed directly to prescribers in about dozen countries through a network of distributors and made available to patients worldwide through an innovative e-commerce platform. Neuroaid is making history in being the first traditional medicine being routinely prescribed by neurologists and neurosurgeons, it is also the focus of CHIMES study, which is the largest ever clinical trial conducted on a traditional medicine in Western medicine hospital outside China. Several centers in Europe have showed interest to join CHIMES trial initiative. Six peer review articles were published over the past two-year showing an intense clinical scientific interest.

In January 2010, a team led by Prof. Lazdunski has established the novel mechanism of action of Neuroaid that shows that it increases neurogenesis, and neurites outgrowth and synaptogenesis, both of this effects can be explained by a novel mechanism to trigger the synthesis and release of the growth factor brain-derived neurotrophic factor (BDNF). In animal models, Neuroaid provided a better post-stroke recovery of neurological functions, when given before stroke as a preventive treatment, or after stroke either immediately or in conditions mimicking delays associated with human hospitalization, Neuroaid reduced the infarct volume. This has proven to be a very convincing scientific validation of Neuroaid beneficial properties already reported for post-stroke treatment in human clinical trials. It also paves the way for a number of derivatives of Neuroaid consisting of a family of simplified formulas with enhanced patient convenient dosage, which will be released by Moleac. Neuroaid II is expected to launch in the second half of 2010.

Moleac has entered into R&D partnerships with leading research institutes in Europe, China and Singapore. This includes CNRS in France for the pharmacology research under the leadership of world-renowned pharmacologist, Prof. Michel Lazdunski, and with 16 leading hospitals in South Asia that are implementing the CHIMES clinical trial, four hospitals in the Philippines led by the University of Santo Tomas hospital and seven hospitals in Thailand led by Siriraj Hospital. Prominent clinicians who are also a part of the partnership include Prof. MG Bousser (France), Prof. G Donnan (Australia) Prof. Chen (Singapore) Prof. Niphon (Thailand), Prof. Navarro (Philippines), and Prof. Asita (Sri Lanka). The partnership has enabled Moleac to identify the potential of Eastern world therapeutics in Western worlds.

Major breakthroughs

Moleac's first product, Neuroaid, now marketed in more than 30 countries, continues to undergo clinical trials to extend its indications. The company has published four scientific papers related to Neuroaid in clinical trials and its pharmacology.

In a short period, since its launch, Neuroaid has become a product with global reach. It has witnessed considerable geographic expansion outside Singapore as it is now available in many countries in the Asia Pacific region, the Middle East, Europe and the US.

Moleac has increased its employee strength from four in 2007 to 20 so as to reach out to the needy patients globally. It also opened two subsidiaries in Europe. The company has completed two rounds of financing in 2008 and 2009, for a combined amount of $4.7 million. The successful launch of the product in Singapore and in other parts of the world has generated sales of $2.11 million.